Related Experiment Video
Updated: May 23, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Phenotypic Consensus Clustering and Treatment Heterogeneity Analysis in Critically Ill Patients with Comorbid Type 2
Xiujuan Chen1, Jiaqi Sun2, Huixian Li1
1Medical Big Data Center, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Guangdong Provincial Key Laboratory of Artificial Intelligence in Medical Image Analysis and Application, Guangzhou, China.
Aims:
This study aimed to establish a phenotypic clustering model for critically ill patients with comorbid type 2 diabetes mellitus (CIP T2DM), define distinct subtypes, and analyze differences in clinical characteristics and treatment response.
Methods:
Patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database were phenotyped based on demographic, physiological, and biochemical parameters, along with critically ill scores, using a consensus clustering algorithm. Subtype validity was assessed using the eICU Collaborative Research Database (eICU). High-frequency combination drug regimens were then extracted to reveal therapeutic heterogeneity among subtypes.
Results:
Three subtypes were identified in the MIMIC-IV cohort (n = 6349). The in-group proportions of 0.957, 0.898, and 0.836 in the eICU cohort (n = 1425) show high consistency. These three subtypes are: a) CIP T2DM with severe infection (CIP T2DM-SI) with a mortality of 16.7% and a post-medication blood glucose (PMBG, first measured 24 h after medication administration) of 8.25 mmol/L; b) CIP T2DM with organ failure (CIP T2DM-OF) with 18.6% mortality and 8.03 mmol/L PMBG; and c) CIP T2DM under monitoring for continuous observation and evaluation (CIP T2DM-UM) with 8.87% mortality and 6.98 mmol/L PMBG. Moreover, the three subtypes showed different in-hospital mortality risks under the same medication regimen.
Conclusions:
Three phenotypes were identified in CIP T2DM, showing significant heterogeneity in clinical characteristics and prognosis. Personalized interventions for these subtypes may help reduce adverse events and guide precise treatment in practice.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Acute Pancreatitis II: Clinical Manifestations and Management

